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age group of 21 -30 years. In study population 141 (61.3%) were married and major-
ity of Housewives 57 (24.8%) followed by Govt. service 28 (12.2%). Amongs study 
population 136 (59.1%) patients received the second generation antipsychotics 
and 8 (3.5%) patients received first generation antipsychotics Resperidone was 
the most commonly prescribed antipsychotic given to 36.5% of the patients fol-
lowed by clozapine 26.5% and olanzapine. Monotherapy was received by 22.2%. 106 
(46.08%) patients and 89 (38.69%) received dual drug regimen. ConClusions: The 
utilization pattern of antipsychotics, revealed that atypical antipsychotics were 
prescribed more commonly when compare to typical antipsychotics. Among the 
atypical antipsychotics, Resperidone was commonly used during Schizophrenia 
as compared to other atypical antipsychotic drugs.
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CoMParison of resourCe use and HealtH Care Costs in new 
initiators of long-aCting injeCtable (lai) and oral seCond 
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objeCtives: To measure health care utilization and costs among new initiators of 
LAI and oral second generation antipsychotics with schizophrenia or bipolar disor-
der. Methods: A large database of a commercially insured US population was used 
to index patients on their first treatment between 1/1/2011 and 12/31/2011. Patients 
were required to have ≥ 12 months pre-index and ≥ 12 months post-index, were new 
users of a second generation antipsychotic, and diagnosed with schizophrenia or 
bipolar disorder during their pre-index period. LAI and oral patients were matched 
1: 3 using propensity scores. Mean differences in annual resource use and costs 
were compared across groups in an unadjusted difference-in-difference analysis: [ 
(LAI post - LAI pre) - (Oral post - Oral pre)]. Results: Initial selection identified 250 
LAI and 8,356 oral treatment patients. Matching resulted in balanced cohorts of 204 
LAI and 612 oral initiators. Annual hospitalizations and ER visits from pre-index 
to post-index was significantly lower in LAI initiators compared to oral initiators. 
Mean annual hospitalizations per LAI patient reduced from 1.09 to 0.51 (p < 0.0001) 
while that of the oral cohort reduced from 0.53 to 0.39 (p = 0.0011). This resulted in 
a net reduction of 0.45 annual hospitalizations per patient in the LAI cohort, using 
the oral cohort as a reference (p < 0.0001). Mean annual ER visits reduced from 
1.72 to 1.03 per LAI patient compared to no change in the oral cohort, resulting in 
a net difference of 0.72 ER visits between the two groups (p < 0.0001). The unad-
justed difference-in-difference analysis showed a relative reduction in total health 
care costs of $4,997 in the LAI cohort compared to the oral cohort. ConClusions: 
Initiating treatment with an LAI resulted in greater reductions in hospitalizations 
and ER visits compared to oral second generation antipsychotic medications in 
patients with schizophrenia or bipolar disease.
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antidePressant use and suiCide rate in england: tHe  
geograPHiC divide
Anderson R., Wilson T., Griffiths M.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: Mental illness is widespread, with 1 in 3 people worldwide reporting 
symptoms indicative of a psychiatric disorder at some point in their lives. The use 
of antidepressants has risen globally and within Europe has been reported to be cor-
related with a reduced suicide rate. The aim of this research is to analyse the use of 
antidepressants in England and identify any trends. Methods: Antidepressant pre-
scribing data for National Health Service (NHS) England from 2003–2012 and from all 
Primary Care Trusts (2010/11–2012/13) and Clinical Commissioning Groups (2013/14) 
were obtained from the Health & Social Care Information Centre. Data were collated 
for the four NHS regional area teams (North, Midlands & East, London, and South) 
and analysed against population size and suicide rates. Results: Antidepressant 
use in England has increased dramatically in recent years and coincides with a 
year-on-year drop in ingredient costs, with 27.7 million prescriptions in 2003 and 
a net ingredient cost of £395.2 million, to 50.2 million prescriptions in 2012 and a 
net ingredient cost of £211.1 million. From 2010 to 2014, almost £1 billion has been 
spent on antidepressants by NHS England, of which almost a third is accounted for 
by the North region. Over 4 years, the average number of prescriptions per 1,000 
population was 1,140.7, 987.4, 888.2 and 540.5 in the North, Midlands & East, South 
and London, respectively. These figures were correlated with a suicide rate of 9.87 
and 7.05 per 100,000 people in the North and London, respectively. ConClusions: 
There is a clear divide within regions of England regarding antidepressant use and 
suicide rate, and the correlation between these two measures was found to be 
opposite to that reported for Europe generally. These findings highlight the impor-
tance of understanding mental illness and the underlying reasons for the wide 
disparity in England.
PMH64
analysis of PresCribing Patterns of atyPiCal antiPsyCHotiCs in  
lHu Caserta
Farina G.1, Menditto E.2, Manna S.1, Pagliaro C.1, Troncone C.1, Putignano D.2, Orlando V.2, 
Linguiti C.1, Buffardi G.F.1, Tari M.G.1
1LHU Caserta, Caserta, Italy, 2CIRFF- Center of Pharmacoeconomics, Naples, Italy
objeCtives: The Local Health Unit Caserta has made web-platform (SANIARP) 
available to specialists and pharmacists to enter the diagnostic and therapeutic 
information of the patient with each prescription. The advantage provided by this 
platform is to make available the information on the analysis of the profiles of 
prescriptive drugs in a large population sample. The aim of study was to evaluate 
prescribing patterns of atypical antipsychotics in LHU Caserta for the years 2011-
2013. Methods: This retrospective cohort study was carried out from the data of 
pharmaceutical prescriptions and of plans therapeutic in Saniarp in the LHU Caserta 
in the 2011-2013. Information about users of atypical antipsychotics were analyzed. 
Information about the diagnosis and treatment plans were obtained through the 
Resource use (pharmacy claims, outpatient claims, emergency room admission 
and hospital admission) and corresponding costs over twelve months after index 
date were compared between groups. Results: Each group included 362 patients. 
Patient characteristics at baseline, resource use, and health care costs before index 
date were comparable between the two groups. At twelve months after the index 
date, patients with no pharmacological treatment had higher resource utilization in 
every category but medication. Total costs over 12 months were $14,983 and $15,692 
in groups with and without pharmacological treatment, respectively (p = 0.67). 
Patients with pharmacological treatment had a higher pharmacy cost, but this was 
offset by the higher cost of outpatient visits in patients with no pharmacological 
treatment. These visits were mostly related to mental disorders, nervous system, 
skin and musculoskeletal disorders and injuries and poisonings. ConClusions: 
While the treatment of opioid dependence with buprenorphine/naloxone is asso-
ciated with higher medication acquisition cost, it is outweighed by cost savings 
in other categories, especially outpatient care. Patients without pharmacological 
treatment use more health care resources and have higher total costs.
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drug utilization study of antiPsyCHotiCs used for tHe HosPital 
treatMent of sCHizoPHrenia in russia
Vaskova L., Tyapkina M.
1st Moscow State Medical University named after I.M. Sechenov, Moscow, Russia
objeCtives: The goal was to examine utilization of typical (TA), atypical antip-
sychotic (AA) and depot antipsychotic s (DA), used for treatment of patients with 
schizophrenia in Russian hospital during 1 year. Methods: A retrospective study, 
carried out in Moscow hospital from January 2012 to December 2012. Patient data 
on demography (age, sex), medicines used (dose, duration of treatment), length of 
hospital stay and clinical outcome were recorded and analyzed. Drug consumption 
was calculated using defined daily dose (DDD) methodology. Results: Total 227 
patients were included in the study. Among study population 121 (53.3%) patients 
were male and mean age was 33.2 (male) and 45.5 (female). Out of 227 patients 219 
(96.5%) were improved and 1 (0.4%) person were recovery. Mean length of hospi-
talization was 75.3 days. Total 27 antipsychotic were used for the treatment schizo-
phrenia among these patients. Among used antipsychotic consumption (DDD/100 
bed days) was highest for AA clozapine oral (194.25) followed by TA haloperidol oral 
(52.39), DA fluphenazine parenteral depot (20.04) and DA haloperidol parenteral 
depot (19.59). However the cost of treatment for AA clozapine was higher, than for 
TA haloperidol. The total consumption (DDD/100 bed days) in the antipsychotics 
group was: 224.3 for AA, 73.38 for TA and 39.91 for DA. ConClusions: This study 
provides estimate of consumptions different antipsychotics used for the hospital 
treatment of schizophrenia. Atypical antipsychotic clozapine oral is highest con-
sumed among 27 antipsychotics. Total drug utilization for AA was three times higher 
than for TA and five times higher than DA, however the costs of treatment for AA 
was substantially higher than for TA.
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objeCtives: - The objective of the study was to provide utilization data in Germany 
for the ADHD stimulant medication lisdexamfetamine dimesylate (LDX) in the first 
six months following its launch in June 2013. Methods: - This drug utilization 
study (DUS) analysed a longitudinal electronic medical record database (IMS Disease 
Analyzer - Germany), and was part of a larger DUS providing data for 8 European 
countries for up to 5 years. The study included records of all patients who had been 
prescribed LDX from June 2013 to December 2013 in the paediatrician panel (PP) 
or neurologist/psychiatrist panel (NPP) of the German database. Results: - The 
analysis included 123 patients (348 prescriptions) from the PP and 296 patients 
(710 prescriptions) from the NPP. In both panels, 91% of patients had a documented 
diagnosis of ADHD. When initiated on LDX treatment, most patients (PP, 98%; NPP, 
91%) were between 6 and 18 years of age; up to 1% of patients in both panels were 
below 6 years of age and 2% and 8% of patients in the PP and NPP, respectively, were 
above 18 years of age. The majority of patients in both panels were male (PP, 77%; 
NPP, 79%). The average prescribed daily dose of LDX was within the recommended 
range (30–70 mg) for all patients in the NPP and for 98.4% in the PP, with a mean 
daily dose across patients of 42 mg in both panels. ConClusions: - The findings of 
this analysis of electronic medical records indicate that, during the first six months 
after launch, LDX was mainly prescribed in Germany within the EMA-approved 
Summary of Product Characteristics (SmPC) with regard to the indicated patients, 
age group and dose regimen.
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Pethekar A.J.1, Nair S.1, Kunhikatta V.1, Sharma P.S.V.N.2, Thunga G1
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objeCtives: The main objective of the study was to find the utilization pattern 
of antipsychotics in schizophrenia patients in a tertiary care teaching hospital 
South India. Methods: A retrospective study has been carried on schizophrenic 
patients admitted in a tertiary care teaching hospital for a period of one year. The 
diagnosis of schizophrenia was based on ICD-10 (Tenth revision) criteria. Patients 
of both sexes who diagnosed with schizophrenia were included in the study. Other 
mental illness or drug induced psychosis patients were excluded from the study. 
All demographical and clinical characteristic including treatment pattern were 
collected and entered. Data were analyzed in SPSS 20.0. Results: Out of 230 
patients, 144 (63%) were males and the majority of patients were 65 (28%) in the 
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dementia, the perspective and inclusion of informal costs is essential. The research 
is funded by the European Commission, ICT FP7, project ID 287509.
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objeCtives: Estimating resource use [RU] in real life is an important part of health 
economic evaluations. RU data should reflect how patients are actually treated. In 
MDD, RU data are mostly obtained from expert opinion. Variability in RU may lead to 
uncertainty in health economic evaluations, but few published studies report these 
data in the detail needed. The present analysis reports RU data by depression health 
state from an observational study. Methods: PERFORM (Prospective Epidemiological 
Research on Functioning Outcomes Related to Major depressive disorder) is a 2-year 
prospective observational study conducted in 5 Western-European countries. Two- and 
six-month RU were estimated by health state: remitters, non-remitters, patients in 
relapse or not. RU included visits to different health care professionals, hospitalization 
and sick leave. Results are reported for the whole study population and are also avail-
able by country (including the UK, for which EQ5-D-derived utilities are also available) 
and for subgroups (e. g., patients who switched antidepressants at baseline). Results: 
Of the 819 analysable patients at 2 months, 29% were in remission. Among patients 
with at least one visit, the frequency of visits to general practitioners, psychiatrists 
and psychotherapists was consistently lower for remitters versus non-remitters (1.8 
vs. 2.4, 2.2 vs. 2.4 and 2.6 vs. 3.1 respectively). Fourteen patients had at least one hos-
pitalisation. Sick leave was less frequent (14% vs. 27%) and shorter (34 vs. 41 days) for 
remitters versus non-remitters respectively. At 6 months, 19.3% of patients relapsed. 
RU were higher with more visits to psychiatrists, psychotherapists (4.0 vs. 2.7, 7.8 
vs. 5.5) for relapsed versus non-relapsed patients. ConClusions: This first analysis 
provides European RU data in MDD. More information is expected at completion of 
the two-year follow-up and this study offers the possibility to describe RU by health 
states, countries and subgroups and assess their transferability to other countries.
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bACKGRound And objeCtives: Economic crisis in Greece has several social impli-
cations, as unemployment and poverty have largely increased during the past years. 
Since the onset of the economic crisis, suicides have marked a significant increase. 
Therefore, aim of this study is to investigate the relationship between suicides and 
the economic crisis and certain macroeconomic indices. Methods: Annual suicide 
rates were obtained from the Hellenic Statistical Authority. Multiple linear regres-
sion analysis with Newey-West standard errors was carried out in order to examine 
the relationship between gender and age specific suicide rates and unemployment, 
GDP per capita and economic crisis (binary variable). Additionally, several statistical 
tests were conducted in order to examine the properties and the robustness of the 
model. Results: Unemployment appears as the major factor affecting suicides of 
men and women above the age of 15. However, gender and age-related differences are 
being observed. Unemployment is positively associated with the suicides of men aged 
15-24, 35-44, 55-64 years. Female suicides are also affected by unemployment, exclud-
ing the age groups of 35-44 and 45-54 years old. Interestingly, suicides of women aged 
between 45-54 and 55-64 were negatively associated with economic crisis. In the total 
population, unemployment has impact on suicides for 15-24, 35-44, 55-64 age groups, 
while economic crisis affects suicide rate in the age group of 25-34. In addition, GDP 
per capita is negatively associated with suicide rates for young men (aged under 24). 
The same effect is also observed for the young population in general. ConClusions: 
The current economic turmoil in Greece affects suicides deaths. According to this 
analysis, unemployment is the main factor that determines age-specific rates and 
essentially point to the direction where measures should be taken in order to control 
suicides’ incidence and lessen the effect of economic crisis on health.
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objeCtives: Population-based approaches to improving health are critical to con-
trolling rising health care costs. US Veterans represent an identifiable population of 
significant interest due to their unique occupational exposures. The objectives of this 
study is to characterize the mental health of a representative US sample specifically 
comparing: non-Veterans, Veterans receiving VA benefits and Veterans not receiving 
VA benefits. Methods: A representative (U.S. ) sample of 2,000 individuals completed 
an online survey assessing their mental health (PHQ-2), Veteran status and receipt of 
Veteran Administration health care benefits. We conducted bivariate analyses among 
the entire population and multivariate logistic regression among 352 Veterans to 
assess the relationship between ones mental health (PHQ-2 score > = 3) and Veteran 
benefit enrollment status controlling for ones self-reported physical health, history 
of combat, awareness of Veteran Crisis Line and sociodemographic factors. Results: 
Overall 28% of Veterans scored positive for depressive symptom based on a score 
of 3 or greater on the PHQ-2 compared to 11% of non-Veterans. However, breaking 
Veterans into those enrolled and those not enrolled revealed that 38% of enrolled 
Veterans were positive compared to just 17% of non-enrolled Veterans. After removing 
insignificant and/or collinear variables from the logistic regression model, the final 
set of independent variables included Vets enrolled in VA benefits OR= 3.91 (1.93- 8.44), 
poor/fair physical health OR= 4.32 (1.98-9.68), age OR= 0.93 (0.91-0.95) and awareness 
of Veteran crisis line 3.12 (1.69- 5.97). ConClusions: Younger veterans in poorer 
physical health whom are receiving VA benefits and are aware of the Veteran Crisis 
line are more likely to have depressive symptoms. Population based approaches to 
linkage between the pharmaceutical database and the SANIARP database, using 
anonymized patient code. Based on the date of the first prescription (index date) 
the following prescribing patterns have been defined: continuers (subjects with 
a gap < 30 days between two prescriptions on-going); intermittent (subjects with 
a gap> 30 days but that receive another prescription at index date); switchers 
(discontinuation of index drug and prescription of a new antipsychotic); add-on 
(addition of a new antipsychotic); as-needed (addition of a new antipsychotic for 
a limited period). Results: We identified 2,768 patients (44.5% females) with at 
least one prescription of atypical antipsychotics and with a diagnosis coded in 
the study period. Schizophrenia is the most frequent indication (31.1%) the most 
prescribed drug is olanzapine (29.1%), followed by risperidone (17.7%), quetiapine 
(13.4%), aripiprazole (12.5%), clozapine (10.3%) and asenapine (3.1%). About 70% of 
schizophrenic patients is treated with the same drug, 7.9% switch and 23.6% is in 
polytherapy. ConClusions: The use of SANIARP, web- platform able to allow the 
systematic monitoring of prescribing patterns of drugs, is of primary importance 
for better health planning.
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objeCtives: Major Depressive Disorders (MDD) guidelines recommend using 
antidepressants with dual mechanism-of-action (venlafaxine, duloxetine) when 
resistant to a prior course of Selective-Serotonin-Reuptake-Inhibitors (SSRI). Dose 
to use should be close to the DDD recommended by WHO. Routine clinical prac-
tice may be frequently far from guidelines. The aim was to ascertain the average 
maintenance daily dose (DD) of venlafaxine and duloxetine in the monotherapy 
of patients with MDD who showed resistance to a previous SSRI in routine medi-
cal practice in Spain. Methods: Retrospective analysis extracting consecutively 
electronic medical records (EMR) of the BSA, a provider which health plan coverage 
includes near 120,000 inhabitants in Badalona (Spain). EMR of male/female patients, 
> 18 years, included in the chronic prescription follow up program, with a MDD 
ICD-9-CM code (296.2x/296.3x), and who were resistant to a previous SSRI course, 
were extracted for analysis. Resistant was defined as persistence of symptoms 
(score > 17 in the Hamilton-Depression scale and/or reduction lower than 30% of the 
baseline score). Maintenance DD was considered the dose repeated (refills) at least 
two time consecutively during the study period (years 2012-2013). Results: Three-
sixty-eight EMR [81% women, 60.3 (15.2) years] were extracted; 160 of duloxetine 
and 208 of venlafaxine. Average maintenance DD were 65mg/day and 117 mg/day 
for duloxetine and venlafaxine, respectively. Demographics, number of comorbidi-
ties or previous SSRI were not related with average dose. 86% of duloxetine EMR 
were prescribed the WHO DDD for this drug (60mg), while only 42% of venlafaxine 
received its WHO DDD (100mg), p< 0.001. Number of DDD per day were significantly 
higher with venlafaxine; 1.17 (1.10-1.23) vs. 1.09 (1.05-1.12), p= 0.049. ConClusions: 
Routine medical practice average maintenance DD of venlafaxine and duloxetine in 
SSRI resistant subjects with MDD are different in terms of both their recommended 
doses in labelling or guidelines and in number of DDD per day.
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objeCtives: Dementia patients are in need of more extensive personal care com-
pared to other long-term care users. This results in a high economic impact of demen-
tia on patients, families and health care systems. Due to the increasing prevalence 
of dementia worldwide, combined with limited health care expenditures, a better 
understanding of resource use in dementia care is needed. Therefore the aim of our 
study is the assessment of resource use in dementia in the most common setting: 
home-based care (informal caregivers). Methods: The Erlanger Dementia Registry 
structure was set up in 2013. Both dementia patients and informal caregivers are 
interviewed separately with internationally approved valid instruments. Follow-up 
takes place after 6, 12 months and afterwards annually. Resource use in dementia is 
assessed via the ‘Resource Utilization in Dementia (RUD) instrument’. Results: A 
total number of 50 informal caregivers (mean age= 63, 61% female, 23% employed, 72% 
live together with the patient) were interviewed after the initial dementia diagnosis 
at baseline, and 22 study participants took part at the 1st follow-up. Informal caregiv-
ers were mainly spouses (72%) and children (22%). Main support was provided for 
instrumental activities of daily living (t0:77%; t6:86%), followed by activities of daily 
living (t0:37%; t6:52%) and supervision (t0:26%; t6:33%). Average hours for support 
6 months after diagnosis were: IADL= 4.3h/day (min= 1.0, max= 16.0), ADL= 5,2h/day 
(min= 2.0, max= 16.0), and supervision= 12.9h/day (min= 1.0, max= 24.0). The average 
monthly costs for informal caregivers 6 months after diagnosis (medication; addi-
tional disease-related costs) are 76 € . ConClusions: Our results highlight the sig-
nificant impact of informal costs (time provided for care) in dementia care, occurring 
early in the disease course. For dementia patients cared for at home, informal costs 
put an additional economic burden on families. For future health policy planning in 
